Memorandum of Understanding on Co-operation between Tamir Biotechnology Inc and US Pharmacia International, Inc.Tamir Biotechnology, Inc. • January 13th, 2012 • Biological products, (no disgnostic substances) • New Jersey
This MOU is an expression of the Parties' intention to negotiate a definitive License Agreement in accordance with the terms contained herein and with the exception of the Confidentiality Provisions this MOU is not a binding agreement. It is the intention of the parties to enter into good faith negotiations and consummate a License Agreement in the Field, in the Territory as will be described for topical formulation of Tamir’s proprietary drug Onconase/Ranprinase for treatment of patients diagnosed with Human Papillioma Virus (HPV). The terms of the MOU lay down the foundation for a definitive License Agreement that the parties shall negotiate and sign within sixty (60) days. Tamir will manufacture under GMP conditions, topical formulation of Onconase which will be used to treat genital and skin warts caused by the HPV. US Pharmacia International Inc. or any of its affiliates (USPI) shall have the exclusive rights to sell and market the product in the Field, in the Territory.
